Nuvalent Surges 39% Premarket. GSK Acquires for $10.6 Billion at 40% Premium, New CEO’s First Big Bet on Lung Cancer Field

TradingKey - British pharmaceutical giant GlaxoSmithKline ( GSK) announced on June 9 that it would acquire U.S. biotechnology company Nuvalent in an all-cash deal worth $10.6 billion ( NUVL) to bolster its lung cancer drug pipeline. This transaction is not only GSK's largest acquisition in over a decade, but also the first major strategic move since new CEO Luke Miels took office.

According to the agreement, GSK will acquire all outstanding shares of Nuvalent at a price of $124 per share, representing a 40% premium over its previous closing price, with an actual investment of approximately $9.4 billion net of cash. Driven by this news, Nuvalent's stock price surged nearly 39% in pre-market trading.

Founded in 2017, Nuvalent focuses on the research and development of precision-targeted anti-cancer drugs. Its core pipeline includes two non-small cell lung cancer (NSCLC) inhibitors currently under FDA review: neladalkib for ALK-positive mutations and zidesamtinib for ROS1-positive mutations.

Both drugs have received Breakthrough Therapy and Orphan Drug designations, with regulatory results expected in September and November 2026, respectively. If successfully launched, CGS analysts project that their combined annual sales could reach $823 million by 2029.

Luke Miels emphasized in a statement that the acquisition will bring immediate, realizable revenue growth opportunities for the company.

He pointed out that Nuvalent's two potential blockbuster drugs are expected to contribute to profits starting in 2027 and will serve as key pillars supporting the company's performance during the patent expiration of core products like dolutegravir between 2028 and 2030. GSK also reaffirmed its 2026 guidance for core operating profit and earnings per share growth of 7%-9%.

The urgency of this acquisition stems from the "patent cliff" challenges facing GSK. The company's flagship product, the shingles vaccine Shingrix, has already shown a declining trend in the U.S. market, while the shadow of patent expirations for the HIV drug portfolio is fast approaching—the division's total revenue reached £7.7 billion in 2025, with sales of the oral combination drug Dovato growing 22% to £2.7 billion, but patent protections will expire successively in the coming years.

Currently, the global biopharmaceutical industry is witnessing a new wave of M&A activity. PitchBook data shows that 201 deals have been completed so far in 2026, with a total value of $106 billion, potentially making it the strongest year since the pre-pandemic peak.